Emergent BioSolutions Looks beyond Biodefence with Trubion Acquisition

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 28 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1382     ISSN: 1756-7874

Section: Mergers & Acquisitions



Emergent BioSolutions, best known for its prophylactic anthrax vaccine BioThrax® (anthrax vaccine adsorbed), has acquired Trubion Pharmaceuticals in order to expand its pipeline beyond infectious diseases and into oncology and autoimmune diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details